CEP-151 (rhIGF-1)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CEP-151 (rhIGF-1), covering 2008-03-04 to 2008-03-04. Get the full timeline:
Most recent: Clinical Trial Update: A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients [Phase 2]